These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29683036)

  • 1. Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders.
    Yildiz A; Güryildirim M; Pepeler MS; Yazol M; Oktar SÖ; Acar K
    Clin Appl Thromb Hemost; 2018 Oct; 24(7):1102-1108. PubMed ID: 29683036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders.
    Kuznetsova PI; Raskurazhev AA; Konovalov RN; Krotenkova MV; Chechetkin AO; Lagoda OV; Melikhyan AL; Tanashyan MM
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
    Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
    Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloproliferative diseases.
    de Lacerda JF; Oliveira SN; Ferro JM
    Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
    Tefferi A; Elliott M
    Semin Thromb Hemost; 2007 Jun; 33(4):313-20. PubMed ID: 17525888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
    Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
    Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.
    Kessler CM
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):10-4. PubMed ID: 15190517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloproliferative Neoplasms: A Contemporary Review.
    Tefferi A; Pardanani A
    JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
    Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
    Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.